Pantogam syrup 10% 100ml

$26.55

More info

Pantogam syrup 10% 100ml

pharmachologic effect  
The spectrum of action of the drug Pantogam associated with the presence in its structure of gamma-aminobutyric acid (GABA). The mechanism of action is due to the direct influence of Pantogam on the GABAB-receptor-channel complex. 
The drug has a nootropic and anticonvulsant action. 
The drug increases the brain's resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, and activates mental and physical performance. Improves GABA metabolism in chronic alcohol intoxication and after the abolition of ethanol. It is able to inhibit acetylation reactions involved in the inactivation mechanisms of procaine (novocaine) and sulfonamides, which results in a prolonged action of the latter. 
It causes inhibition of the pathologically increased gallbladder reflex and detrusor tone. 

Pharmacokinetics
  
Suction 
Quickly absorbed from the digestive tract. 
Distribution 
The greatest concentrations are in the liver, kidneys, in the wall of the stomach, in the skin. Penetrates the BBB.
Metabolism and excretion 
Not metabolized and excreted unchanged within 48 hours. 67.5% of the taken dose is excreted by the kidneys, 28.5% - with feces. 

Dosage  
pills and syrup are taken orally in 15-30 minutes after eating. pills are used in children over 3 years of age, at an earlier age they recommend taking the drug in the form of syrup. 
For adults, a single dose is 0.25-1 g, daily - 1.5-3 g. 
For children, a single dose is 0.25-0.5 g, daily - 0.75-3 g. 
The course of treatment is 1-4 months, sometimes up to 6 months. After 3-6 months, you can repeat the course of treatment. 
In schizophrenia (in combination with psychotropic drugs), the drug is prescribed in a dose of 0.5-3 g / day. The course of treatment is from 1 to 3 months. 
In epilepsy (in combination with anticonvulsants), the drug is prescribed in a dose of from 0.75 g to 1 g per day. The course of treatment is up to 1 year or more. 
When extrapyramidal neuroleptic syndrome (in combination with ongoing therapy), the dose is up to 3 g / day. The treatment is carried out for several months. 
When extrapyramidal hyperkinesis in patients with hereditary diseases of the nervous system (in combination with therapy) is prescribed from 0.5 g to 3 g per day. The course of treatment is up to 4 months or more. 
With the consequences of neuroinfections and head injuries - 0.25 g 3-4 times / day. 
To restore health at increased loads and asthenic conditions, Pantogum is prescribed 0.25-0.5 g 3 times / day. 
For the treatment of extrapyramidal syndrome caused by the administration of neuroleptics, adults - 0.5-1 g 3 times / day, children - 0.25-0.5 g 3-4 times / day. The course of treatment is 1-3 months. 
For children with ticks - 0.25-0.5 g 3-6 times / day for 1-4 months. 
When urination disorders for adults, the drug is prescribed in a dose of 0.5-1 g 2-3 times / day, for children - 0.25-0.5 g each (daily dose is 25-50 mg / kg). The course of treatment is 1-3 months. 
The following dose range is recommended for children with various pathologies of the nervous system depending on age: children of the first year of life - 0.5-1 g / day, children under 3 years old - 0.5-1.25 g / day, children from 3 to 7 years old - 0.75- 1.5 g / day, children over 7 years old - 1-2 g / day. The tactics of the drug is to gradually increase the dose within 7-12 days, taking the maximum dose for 15-40 days and gradually reducing the dose for 7-8 days until complete withdrawal of Pantogam. The course of treatment is 30-90 days (for individual diseases up to 6 months or more). 
The break between coursework Pantogam is 1-3 months (as for any other nootropic drugs). 
Taking into account the nootropic action of the drug, its reception is carried out in the morning and afternoon hours (up to 17 h). 

Overdose  
Symptoms: increased symptoms of the described side effects (sleep disturbance or drowsiness, noise in the head). 
Treatment: activated carbon, gastric lavage; if necessary, conduct symptomatic therapy. 

Drug interaction  
Pantogam prolongs the action of barbiturates, enhances the effects of anticonvulsants. 
When used together, Pantogam prevents the side effects of phenobarbital, carbamazepine, antipsychotics. 
The effect of Pantogam increases with simultaneous use with glycine, etidronic acid. 
Pantogam potentiates the action of local anesthetics (procaine). 

Pregnancy and lactation  
The drug is not recommended for use during pregnancy and lactation (breastfeeding) due to lack of data efficacy and safety. 

Side effects
  
Allergic reactions: possible rhinitis, conjunctivitis, skin rash (may require removal of the drug or dose reduction). 
Other: possible sleep disturbance or drowsiness, noise in the head (these symptoms are usually short-lived and do not require discontinuation of the drug). 

Terms and conditions of storage  
The drug should be stored in a dry, dark place and out of reach of children at a temperature not exceeding 25 &№176; C. Shelf life of pills 250 mg - 4 years, pills 500 mg - 3 years, syrup - 2 years. 
After opening store the bottle with syrup in the refrigerator for no more than 1 month. 

Indications  
- cognitive impairment with organic brain lesions (including the effects of neuroinfections and traumatic brain injuries) and neurotic disorders; 
- schizophrenia with organic cerebral insufficiency; 
- cerebrovascular insufficiency caused by atherosclerotic changes of cerebral vessels; 
- extrapyramidal disorders (including myoclonus epilepsy, Huntington’s chorea, hepatolenticular degeneration, Parkinson’s disease), as well as for the treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by the administration of neuroleptics; 
- epilepsy with a slowdown of mental processes in complex therapy with anticonvulsants; 
- psycho-emotional overload, reduced mental and physical performance (to improve concentration and memorization); 
- Neurogenic disorders of urination (pollakiuria, urgency, imperative urinary incontinence, enuresis); 
- children with perinatal encephalopathy from the first days of life; 
- various forms of cerebral palsy; 
- mental retardation of varying degrees, incl. with behavioral disorders; 
- violations of the psychological status of children in the form of a general delay in mental development, specific speech disorders, motor functions and their combination, the development of school skills (reading, writing, counting, etc.); 
- hyperkinetic disorders, incl. attention deficit hyperactivity disorder; 
- neurosis-like states (at stuttering, mainly clonic form, tics, inorganic encopresis and enuresis). 

Contraindications  
- acute severe kidney disease; 
- pregnancy;style="font-family: arial; fon>